Evelo Biosciences Stock Current Asset
| EVLODelisted Stock | USD 8.23 2.68 24.56% |
Evelo Biosciences fundamentals help investors to digest information that contributes to Evelo Biosciences' financial success or failures. It also enables traders to predict the movement of Evelo Pink Sheet. The fundamental analysis module provides a way to measure Evelo Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evelo Biosciences pink sheet.
Evelo |
Evelo Biosciences Company Current Asset Analysis
Evelo Biosciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Evelo Biosciences Current Asset | 49.29 M |
Most of Evelo Biosciences' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evelo Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Evelo Biosciences has a Current Asset of 49.29 M. This is 97.71% lower than that of the Biotechnology sector and 95.35% lower than that of the Health Care industry. The current asset for all United States stocks is 99.47% higher than that of the company.
Evelo Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evelo Biosciences' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evelo Biosciences could also be used in its relative valuation, which is a method of valuing Evelo Biosciences by comparing valuation metrics of similar companies.Evelo Biosciences is currently under evaluation in current asset category among its peers.
Evelo Fundamentals
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 83.13 % | ||||
| Number Of Shares Shorted | 430.1 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) | ||||
| Net Income | (114.53 M) | ||||
| Cash And Equivalents | 92.01 M | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 51.14 M | ||||
| Debt To Equity | 1.55 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (101.23 M) | ||||
| Short Ratio | 0.42 X | ||||
| Earnings Per Share | (15.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 66 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 7 M | ||||
| Total Asset | 64.44 M | ||||
| Retained Earnings | (529.22 M) | ||||
| Working Capital | 39.18 M | ||||
| Current Asset | 49.29 M | ||||
| Current Liabilities | 4.32 M | ||||
| Z Score | -16.24 | ||||
| Net Asset | 64.44 M |
About Evelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evelo Pink Sheet
Moving against Evelo Pink Sheet
| 0.72 | VIGL | Vigil Neuroscience | PairCorr |
| 0.54 | VALN | Valneva SE ADR | PairCorr |
| 0.51 | DTIL | Precision BioSciences | PairCorr |
| 0.5 | DOMH | Dominari Holdings | PairCorr |
| 0.47 | DNTH | Dianthus Therapeutics | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |